Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 315

Sort by

Sort Order Select

Journal Articles

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Josephine Anne Lucero, Maria Perusini, Aniket Bankar, Marta Davidson, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Dawn Maze, Karen W.L. Yee, Mark Minden, Steven Chan, Jose-Mario Capo-Chichi, Vikas Gupta, Hassan Sibai, Anne Tierens, Dennis Kim

Blood (2025) 146 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2025-7051

Published: 2025

Journal Articles

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Om Raval, Lilly Gu, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2025-2812

Published: 2025

Journal Articles

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Sara Scott, Ajay Nooka, Jonathan Kaufman, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Nisha Joseph

Blood (2025) 146 (Supplement 1): 2811.

https://doi.org/10.1182/blood-2025-2811

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

Aarya Murali, Zahra AlHaj Issa, Cristiano Machado De Freitas, Akhil Rajendra, Marta Davidson, Aniket Bankar, Hassan Sibai, Maria Perusini, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2025-3508

Published: 2025

Journal Articles

In silico structural biology studies inform the identification of “druggable” pockets in previously understudied dependencies with tumor type/lineage-selective roles.

Evangelos Papadopoulos, Ricardo De Matos Simoes, Olga Dashevsky, Huihui Tang, Eleni Anastasakou, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Yuefang Deng, Aktas Bertal, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 2581.

https://doi.org/10.1182/blood-2025-2581

Published: 2025

Journal Articles

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

Shannon Matulis, Jonathan Patton, Rebecca Owens, Robert Chavez, Arun Wiita, Mala Shanmugam, Constantine Mitsiades, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise

Blood (2025) 146 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2025-2177

Published: 2025

Journal Articles

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Huihui Tang, Ricardo De Matos Simoes, Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Eleni Anastasakou, Oliver Bohorquez, Shizuka Yamano, Evangelos Papadopoulos, Lisa Leypoldt, Arun Wiita, Olwyn Mahon, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 2173.

https://doi.org/10.1182/blood-2025-2173

Published: 2025

Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Blood (2025) 146 (Supplement 1): 910.

https://doi.org/10.1182/blood-2025-910

Published: 2025

Journal Articles

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

Olga Dashevsky, Ricardo De Matos Simoes, Huihui Tang, Torsten Steinbrunn, Shizuka Yamano, Eleni Anastasakou, Benjamin Barwick, Sara Gandolfi, Ryosuke Shirasaki, Vikas Gupta, Michal Sheffer, Jonathan Licht, Lawrence Boise, Matthew Oser, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 688.

https://doi.org/10.1182/blood-2025-688

Published: 2025

Journal Articles

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Akhil Rajendra, Dawn Maze, Aniket Bankar, Steven Chan, Marta Davidson, Vikas Gupta, Mark Minden, Maria Perusini, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Elliot Smith, Karen W.L. Yee, Hassan Sibai

Blood (2025) 146 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2025-1672

Published: 2025

Journal Articles

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Jonathan Kaufman, Efstathios Kastritis, Nisha Joseph, Maria Gavriatopoulou, Lilly Gu, Craig Hofmeister, Vikas Gupta, Evangelos Terpos, Ajay Nooka, Sagar Lonial, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 407.

https://doi.org/10.1182/blood-2025-407

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Ajay Nooka, Nisha Joseph, Madhav Dhodapkar, Vikas Gupta, Craig Hofmeister, Manali Rupji, Bryan Burton, Hafsa Ahmed, Darrian Linton, Stephen Noga, Thomas Lin, Lawrence Boise, Jonathan Kaufman, Sagar Lonial

Blood (2025) 146 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2025-5843

Published: 2025

Journal Articles

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Kiran Lakhani, Yu Zhang, Jonathan Keats, Vikas Gupta, Sagar Lonial, Nisha Joseph, Ajay Nooka, Benjamin Barwick, Lawrence Boise

Blood (2025) 146 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2025-2251

Published: 2025

Journal Articles

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Torsten Steinbrunn, Arnold Bolomsky, Ryosuke Shirasaki, Omar Al-Odat, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Oliver Bohorquez, Brian Glassner, Eleni Anastasakou, Vikas Gupta, Jonathan Licht, Benjamin Barwick, Lawrence Boise, Ricardo De Matos Simoes, James Christensen, Ryan Young, Constantine Mitsiades

Blood (2025) 146 (Supplement 1): 327.

https://doi.org/10.1182/blood-2025-327

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Dominique Mosley, Richa Parikh, Sara Scott, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 3968.

https://doi.org/10.1182/blood-2025-3968

Published: 2025

Journal Articles

Functional genomic screens identify positive and negative regulators of venetoclax resistance

Beena Thomas, Karanpreet Bhatia, Devin Bog, Benjamin Barwick, Constantine Mitsiades, Lawrence Boise, Vikas Gupta

Blood (2025) 146 (Supplement 1): 5733.

https://doi.org/10.1182/blood-2025-5733

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

In silico structural biology studies inform the identification of “druggable” pockets in previously understudied dependencies with tumor type/lineage-selective roles.

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

Identification of novel “driver” genes of multiple myeloma through genome-scale CRISPR activation studies

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Negative regulators of survival and proliferation (NRSPs) identified by CRISPR activation studies in multiple myeloma (MM) vs. other neoplasias: Therapeutic implications

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries

Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Functional genomic screens identify positive and negative regulators of venetoclax resistance

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only